NASDAQ:MEIP
MEI Pharma Stock News
$3.15
+0.220 (+7.51%)
At Close: May 17, 2024
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
10:38am, Tuesday, 14'th May 2024
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible viola
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
08:02am, Thursday, 11'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
08:00am, Wednesday, 10'th Apr 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
01:06pm, Thursday, 15'th Feb 2024
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible viola
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
07:16pm, Tuesday, 13'th Feb 2024
MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $1.66 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to earnings of $1.60 per share a year ago.
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
05:05pm, Tuesday, 13'th Feb 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
05:00pm, Tuesday, 16'th Jan 2024
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
11:31am, Thursday, 14'th Dec 2023
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible viola
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
12:00pm, Monday, 11'th Dec 2023
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
04:57pm, Monday, 06'th Nov 2023
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to
MEI Pharma Recommends Stockholders Not to Consent
05:33pm, Tuesday, 17'th Oct 2023
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has filed a definitive consent revocation statement with the U.S. Securities and Exchange Commis
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
06:00am, Monday, 02'nd Oct 2023
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its Board of Directors has unan
All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy
01:32pm, Friday, 29'th Sep 2023
MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions
05:00pm, Thursday, 28'th Sep 2023
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “MEI” or “the Company”) today issued the following statement in response to the consent solicitation initiated by a group led b
